CARs designed to target VEGFR1 and VEGFR2 have demonstrated potential in eradicating tumor vasculature, limiting tumor cell proliferation, and impeding the supply of nutrition and oxygen to tumors.135, 136. The gene discussed is FLT1; the disease is neoplasm.